Monte Rosa Therapeutics presents promising preclinical data on MRT-8102, a potential treatment for cardiovascular and cardiometabolic diseases at the American Heart Association’s Scientific Sessions 2025. The data supports NEK7 as a novel therapeutic approach to modulate the NLRP3 inflammasome. Initial data from a Phase 1 study is expected in the first half of 2026. A poster presentation on November 8 will detail the selective degradation of NEK7 by MRT-8102. NEK7 is crucial for NLRP3 inflammasome activation, and MRT-8102 shows promise in inhibiting inflammatory cytokines and cholesterol crystal-induced inflammation in cardiovascular diseases. This unique approach could have therapeutic application in various diseases.

Read more at GlobeNewswire: Monte Rosa Therapeutics Presents Preclinical Data at AHA